| Prev Close | 119.18 |
| Open | 119.00 |
| Day Low/High | 114.74 / 119.81 |
| 52 Wk Low/High | 61.61 / 115.14 |
| Volume | 6.44M |
Abbott Laboratories (ABT)
116.01
3.17
2.66
NYSE
| Exchange | NYSE |
| Shares Outstanding | 1771.53B |
| Market Cap | 217.07B |
| P/E Ratio | 60.02 |
| Div & Yield | N.A. (N.A) |
Abbott Laboratories Is Set for Another Breakout
Look to buy at the current market level.
Cramer: You Can't Bet Against the Bonds
A rotation that started as the minor chord of the rotational symphony and is now the major one.
Abbott Laboratories Saw a Recent Breakout
Barring a close below $46, we are likely to see ABT remain firm and work higher.
Cramer: You Need 2 Monday Morning Game Plans
We really want to shake out the weak hands here.
With Mother's Day Coming Up: Who Are the Best Employers for Working Moms?
Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.
Cramer: There Are Powerful Themes in Several Bull Markets
It's a wonder to me how split this market really is.
Good Medicine Makes for 3 Good Charts
Medtronic, Abbott Labs and Becton Dickinson appear to be offering buying opportunities.
Midday Report: Morgan Stanley Boosts Financials; IBM Drags Dow Into Red
Earnings take center stage again with a disappointment from IBM and a better-than-expected performance from Morgan Stanley dividing markets.
Stocks That Are Changing Direction
These charts are showing bullish or bearish reversals.
Cramer: The Best Performers Show No Signs of Letting Up
Their overseas business has been carrying them.
Cramer: We Have Nothing to Distinguish the Stocks Right Now
We know that we are in the era when index managers are ascendant.
Abbott Labs Is Set to Go Substantially Higher
Here are the levels to watch and act on.
Cramer: Top 10 Bull Markets Right Now
Bull market number one, perhaps of all time: the financials.
Cramer: Money's Being Thrown at Almost Everything in the Market
There are nearly too many surging sectors to count.
Bullish and Bearish Reversals for the Week
These stocks are indicating a change in direction.
A Play on Intel's Breakdown
With trend favoring the bears, I'm favoring a bearish call spread.
Abbott Labs: Diagnosing Growth in 2017
ABT could be on course for 10% earnings growth this year, but will investors reward the company with a higher share price?
Dump These 5 'Toxic Stocks' Before the New Year
Start 2017 on the right foot by selling your holdings in these five stocks.
Abbott Laboratories Can Merge With St. Jude Medical: FTC
The Federal Trade Commission says Abbott Laboratories can proceed with its proposed $25 billion acquisition of St. Jude Medical.
Top 5 Dividend Stocks to Buy Now for 2017
Here is a look at some stocks that are poised for excellent dividend returns in 2017.
Abbott Labs Is Likely to See Further Weakness
Look for ABT's declining trend to continue a while longer.
The Good, the Bad and the Ugly
"You see, in this world there's two kinds of people, my friend: Those with loaded guns and those who dig. You dig." -- Blondie in "The Good, the Bad and the Ugly." I did very little today. Markets were higher from the get-go and seemed "stuck" nea...
Abbott Labs Shares Climb on Better-Than-Expected Earnnigs
Shares of the medical-device giant were climbing after unveiling strong earnings.
Jim Cramer: Drug Stocks Feeling Political Pressure
Political pressure is weighing on drug and medical device stocks including Abbott Labs and St. Jude, says Jim Cramer.
Jim Cramer: St. Jude Battery Woes Big But Not a Dealbreaker
St. Jude's warning about battery risks in its implanted heart devices are big but will likely not disrupt its deal with Abbott Labs.
Closing Bell: LionsGate's 'Blair Witch' Set to Own Box Office; U.S. Stocks Fall
U.S. stocks ended Friday's session lower as a crude oil selloff pressures the energy sector and nerves over next week's Federal Reserve meeting peak.
4 Market Segments to Avoid
These sectors are full of high-priced, low-growth stocks.
Cramer: The Answer to This Market: Part 1
The leadership is quite stark.
